Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • USFDA issues warning...

    USFDA issues warning letter to USV Pvt over Daman plant

    Written by supriya kashyap kashyap Published On 2017-03-25T10:59:16+05:30  |  Updated On 25 March 2017 10:59 AM IST

    New Delhi : The US health regulator has red-flagged Mumbai-based drug firm USV Pvt Ltd for violations of manufacturing norms, including data integrity issues, at its Daman facility.


    In a warning letter, the US Food and Drug Administration (USFDA) said the firm failed to establish laboratory controls designed to make sure components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity at its plant. The firm also "failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that includes validation of all aseptic and sterilisation processes", the USFDA said.


    The regulator stated that it had reviewed the company's July 1, 2016, response in detail and also acknowledged receipt of subsequent correspondence, but the response was inadequate.


    Acknowledging that firm was using a consultant to audit operation and assist in meeting FDA requirement, the regulator said: "Your quality system does not adequately ensure the accuracy and integrity of data to support safety, effectiveness, and quality of the drugs you manufacture."


    The warning letter to Managing Director Prashant K Tewari raised similar current good manufacturing practice (CGMP) violations at its other facilities.


    "These repeated problems at multiple sites demonstrate that your company's oversight and control over the manufacture of drugs is inadequate," the FDA noted.


    The regulator said it had reviewed the company's July 1, 2016, response in detail and also acknowledged receipt of subsequent correspondence.


    "Until the company corrects all violations completely and we confirm your compliance with CGMP, the FDA may withhold approval of any new applications or supplements listing your firm as a drug manufacturer," it added.


    Failure to correct these violations may also result in the FDA refusing admission of articles manufactured at the Daman facility, the USFDA said.

    cGMPcurrent good manufacturing practiceDaman plantFDA Warning LetterPrashant K TewariUS Food and Drug AdministrationUSFDAwarning letter
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok